Loading
Life sciences · Review
Future Oncology · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Esophagogastric cancer (EGC) remains a leading cause of cancer‑related mortality worldwide. Approximately 15-20% of advanced EGC overexpress human epidermal growth factor receptor 2 (HER2). Since 2010, trastuzumab in combination with platinum and fluoropyrimidine chemotherapy has been the cornerstone of first-line therapy for HER2-positive advanced EGC, with a modest overall survival benefit. The addition of pembrolizumab to trastuzumab and chemotherapy in the KEYNOTE-811 trial has improved outcomes in PD-L1‑positive tumors. Despite these advances, median overall survival remains below 20 months. Zanidatamab is a novel biparatopic HER2-directed antibody, designed to bind to two distinct extracellular domains of HER2, promoting receptor clustering, enhanced internalization, and immune-mediated cytotoxicity. This Drug Evaluation reviews the pharmacology, pharmacokinetics, clinical development, efficacy, safety, and regulatory status of zanidatamab in HER2-positive EGC. The phase III HERIZON-GEA-01 trial evaluated zanidatamab (with or without tislelizumab) plus chemotherapy as first-line treatment for HER2-positive advanced EGC. This trial demonstrated clinically meaningful improvements in progression-free and overall survival versus trastuzumab-based therapy, leading to FDA approval of zanidatamab plus chemotherapy, with or without tislelizumab, as first‑line treatment for HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. Key questions remain regarding optimal patient selection, the role of tislelizumab across PD-L1 subgroups, sequencing with antibody-drug conjugates, and long-term safety.